menu
    • menu
    [{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Halozyme Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Halozyme Therapeutics \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ GSK"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Janssen Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Halozyme Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ Janssen Biotech"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Halozyme Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Halozyme Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Halozyme Therapeutics \/ Inapplicable"}]

    Find Oncology Clinical Drug Pipeline Developments & Deals by Halozyme Therapeutics

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Halozyme Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Halozyme Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amivantamab,Lazertinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CHMP Issues Positive Opinion for SC Rybrevant® in Advanced EGFR+ NSCLC

                            Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is indicated in combination with Lazertinib for EGFR exon 19 deletions or exon 21 L858R substitution mutations NSCLC.

                            Product Name : Rybrevant

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 03, 2025

                            Lead Product(s) : Amivantamab,Lazertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Halozyme Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Halozyme Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atezolizumab,Human hyaluronidase PH20 enzyme

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Halozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab For Subcuta...

                            Details : The poster concluded that atezolizumab utilizing ENHANZE® was well tolerated, provided similar exposure as atezolizumab IV and that results support further development of subcutaneous atezolizumab in IMscin001 Part 2, a confirmatory phase III study.

                            Product Name : Tecentriq

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 17, 2020

                            Lead Product(s) : Atezolizumab,Human hyaluronidase PH20 enzyme

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Halozyme Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Halozyme Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daratumumab,Recombinant Human Hyaluronidase PH20 Enzyme

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : GSK

                            Deal Size : $10.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Halozyme to Receive $10 Million Milestone Payment From Janssen

                            Details : The milestone payment is associated with the first commercial sale in the European Union of Janssen's subcutaneous formulation of DARZALEX® (daratumumab) utilizing ENHANZE®, which was recently granted marketing authorization by the European Commission.

                            Product Name : Darzalex

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            June 22, 2020

                            Lead Product(s) : Daratumumab,Recombinant Human Hyaluronidase PH20 Enzyme

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : GSK

                            Deal Size : $10.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Halozyme Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Halozyme Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daratumumab,Hyaluronidase

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Janssen Biotech

                            Deal Size : $15.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Halozyme To Receive $15 Million Milestone Payment From Janssen

                            Details : The milestone payment is associated with the first commercial sale in the United States of Janssen's DARZALEX FASPROTM (daratumumab and hyaluronidase - fihj) utilizing ENHANZE®, which was recently approved by the U.S. Food and Drug Administration.

                            Product Name : Darzalex

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            May 14, 2020

                            Lead Product(s) : Daratumumab,Hyaluronidase

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Janssen Biotech

                            Deal Size : $15.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Halozyme Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Halozyme Therapeutics

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daratumumab,Recombinant Human Hyaluronidase PH20 Enzyme

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Halozyme Announces Upcoming Data Presentations at ASH Annual Meeting For APOLLO and ANDROMEDA Phase 3 Studies ...

                            Details : Primary data from the Phase 3 APOLLO study of SC daratumumab in combination with pomalidomide and dexamethasone (D-Pd) in patients with multiple myeloma who have received one or more prior lines of therapy will be the subject of an oral presentation and ...

                            Product Name : Darzalex Faspro

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 11, 2020

                            Lead Product(s) : Daratumumab,Recombinant Human Hyaluronidase PH20 Enzyme

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth